加速英夫利西单抗诱导对急性重症溃疡性结肠炎短期和长期结局的影响:回顾性多中心研究与荟萃分析
该回顾性多中心研究纳入2005至2017年3个中心213例激素难治性急性重症溃疡性结肠炎(ASUC)接受英夫利西单抗挽救治疗的患者,比较加速诱导与标准诱导的结肠切除率,并行荟萃分析。回顾性分析及荟萃分析均未发现加速诱导与较低结肠切除率相关,但不能排除疾病严重程度混杂,需随机试验验证。
要点
- 加速组与标准组院内结肠切除率分别为9%和8%,校正比值比1.35(95%CI 0.38-4.82)。
- 两组在3、6、12、24个月结肠切除比例均无显著差异(所有比较P > .20)。
- 荟萃分析纳入7项研究,加速组181例、标准组436例,短期和长期结局均无显著差异。
核心结论
- 回顾性研究和荟萃分析未发现加速英夫利西单抗诱导治疗与急性重症溃疡性结肠炎患者较低结肠切除率相关。
- 不能排除疾病严重程度混杂,需随机试验比较这些治疗策略。
研究设计与样本
- 回顾性多中心研究,收集2005年至2017年3个中心213例激素难治性急性重症溃疡性结肠炎接受英夫利西单抗挽救治疗的患者数据。
- 患者分为标准治疗组(第0、2、6周给予5mg/kg英夫利西单抗)或加速治疗组(>5mg/kg英夫利西单抗,间隔更短)。
- 主要结局为院内及3、6、12、24个月结肠切除,多变量回归模型校正相关混杂因素。
- 另对已发表的标准化与加速英夫利西单抗治疗急性重症溃疡性结肠炎效果进行荟萃分析。
主要发现
- 回顾性分析中,81例接受加速英夫利西单抗治疗,132例接受标准英夫利西单抗治疗。
- 两组特征无差异,包括C反应蛋白或白蛋白水平。
- 两组院内结肠切除比例相似:加速治疗组9% vs 标准治疗组8%,校正比值比1.35(95%CI 0.38-4.82)。
- 两组在3、6、12或24个月结肠切除比例无显著差异(所有比较P > .20)。
- 加速组中,初始剂量10mg/kg与初始接受5mg/kg后后续剂量5mg/kg或更高者相比,结肠切除率较低。
关键数值与推荐
- 标准治疗:5mg/kg英夫利西单抗在第0、2、6周给药。
- 加速治疗:>5mg/kg英夫利西单抗,间隔更短。
- 主要结局:院内及3、6、12、24个月结肠切除。
- 院内结肠切除:加速组9% vs 标准组8%,校正比值比1.35(95%CI 0.38-4.82)。
- 3、6、12、24个月结肠切除比例组间比较均P > .20。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不能排除疾病严重程度混杂。
- 需随机试验比较这些治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with acute severe ulcerative colitis (ASUC), standard infliximab induction therapy has modest efficacy. There are limited data on the short-term or long-term efficacy of accelerated infliximab induction therapy for these patients. METHODS: In a retrospective study, we collected data from 213 patients with steroid refractory ASUC who received infliximab rescue therapy at 3 centers, from 2005 through 2017. Patients were classified that received standard therapy (5mg/kg infliximab at weeks 0, 2, and 6) or accelerated therapy (>5mg/kg infliximab at shorter intervals). The primary outcome was colectomy in-hospital and at 3, 6, 12, and 24 months. Multivariable regression models were adjusted for relevant confounders. We also performed a meta-analysis of published effects of standard vs accelerated infliximab treatment of ASUC. RESULTS: In the retrospective analysis, 81 patients received accelerated infliximab therapy and 132 received standard infliximab therapy. There were no differences in characteristics between the groups, including levels of C-reactive protein or albumin. Similar proportions of patients in each group underwent in-hospital colectomy (9% receiving accelerated therapy vs 8% receiving standard therapy; adjusted odds ratio, 1.35; 95% CI, 0.38-4.82). There was no significant difference between groups in proportions that underwent colectomy at 3, 6, 12, or 24 months (P > .20 for all comparisons). Among those in the accelerated group, an initial dose of 10 mg/kg was associated with a lower rate of colectomy compared to patients who initially received 5 mg/kg followed by subsequent doses of 5mg/kg or higher. Our systematic review identified 7 studies (181 patients receiving accelerated infliximab and 436 receiving standard infliximab) and found no significant differences in short- or long-term outcomes. CONCLUSION: In a retrospective study and meta-analysis, we found no association between accelerated infliximab induction therapy and lower rates of colectomy in patients with ASUC, compared to standard induction therapy. However, confounding by disease severity cannot be excluded. Randomized trials are warranted to compare these treatment strategies.
引用
- Nalagatla N, Falloon K, Tran G, et al. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID: 29944926. doi:10.1016/j.cgh.2018.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。